Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor

Mol Cancer Ther (2023) 22 (12_Supplement): LB_A12.

https://doi.org/10.1158/1535-7163.TARG-23-LB_A12

Published: 01 December 2023

View articletitled, Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor

Journal Articles

Abstract C067: Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors

Goldy C. George, Sarina A Piha-Paul, Siqing Fu, Ecaterina Dumbrava, Vivek Subbiah, Apostolia Tsimberidou, George Blumenschein, Shubham Pant, Grace Appleton, Laila Noor, Jordi Rodon Ahnert, Timothy Yap, Funda Meric-Bernstam, Charles Cleeland, Tito Mendoza, David S Hong

Mol Cancer Ther (2023) 22 (12_Supplement): C067.

https://doi.org/10.1158/1535-7163.TARG-23-C067

Published: 01 December 2023

View articletitled, Abstract C067: Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors

Journal Articles

Abstract P223: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors

Ignacio Garrido-Laguna, Patrick M. Dillon, Sujan Kabir, Jian Mei, Mark L. Wade, Huyuan Yang, Carl Stapinski, Jason M. Foulks, Steven L. Warner, Clifford Whatcott, Claudia Lebedinsky, Siqing Fu

Mol Cancer Ther (2021) 20 (12_Supplement): P223.

https://doi.org/10.1158/1535-7163.TARG-21-P223

Published: 01 December 2021

View articletitled, Abstract P223: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors

Journal Articles

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald S. Falchook, Michelle A. Fanale, Maria E. Cabanillas, Filip Janku

Mol Cancer Ther (2018) 17 (3): 671–676.

https://doi.org/10.1158/1535-7163.MCT-17-0673

Published: 28 February 2018

View articletitled, Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Journal Articles

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

Mol Cancer Ther (2018) 17 (1_Supplement): A096.

https://doi.org/10.1158/1535-7163.TARG-17-A096

Published: 01 January 2018

View articletitled, Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

Journal Articles

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J. Jack Lee, David Hong, Razelle Kurzrock

Mol Cancer Ther (2016) 15 (10): 2475–2485.

https://doi.org/10.1158/1535-7163.MCT-16-0196

Published: 02 October 2016

View articletitled, TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Includes: Supplementary data

Journal Articles

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Mol Cancer Ther (2016) 15 (6): 1397–1404.

https://doi.org/10.1158/1535-7163.MCT-15-0712

Published: 02 June 2016

View articletitled, BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Includes: Supplementary data

Journal Articles

Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Van Morris, Filip Janku, Helen Huang, Siqing Fu, Michael Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia Tsimbierdou, David Fogelman, Imad Shurieqi, Shanequa Manuel, Antonio Scamardo, Richard Lanman, Nicolas Sommer, David Hong, Scott Kopetz

Mol Cancer Ther (2015) 14 (12_Supplement_2): A36.

https://doi.org/10.1158/1535-7163.TARG-15-A36

Published: 01 December 2015

View articletitled, Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Journal Articles

Abstract C44: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers

Muhammad Rizwan Khawaja, Vinu Madhusudanannair, Chaan Ng, Alpa Nick, Filip Janku, Sarina Piha-Paul, Robert Coleman, Pamela Soliman, Siqing Fu, David Hong, Daniel Karp, Vivek Subbiah, Apostolia Tsimberidou, Funda Meric-Bernstam, Karen Lu, Aung Naing

Mol Cancer Ther (2015) 14 (12_Supplement_2): C44.

https://doi.org/10.1158/1535-7163.TARG-15-C44

Published: 01 December 2015

View articletitled, Abstract C44: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers

Journal Articles

Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

Prasanth Ganesan, Stacy Moulder, J. Jack Lee, Filip Janku, Vicente Valero, Ralph G. Zinner, Aung Naing, Siqing Fu, Apostolia M. Tsimberidou, David Hong, Bettzy Stephen, Philip Stephens, Roman Yelensky, Funda Meric-Bernstam, Razelle Kurzrock, Jennifer J. Wheler

Mol Cancer Ther (2014) 13 (12): 3175–3184.

https://doi.org/10.1158/1535-7163.MCT-14-0358

Published: 04 December 2014

View articletitled, Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

Includes: Supplementary data

Journal Articles

Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations

Prasanth Ganesan, Filip Janku, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha-Paul, Siqing Fu, Vanda M. Stepanek, J. Jack Lee, Rajyalakshmi Luthra, Michael J. Overman, E. Scott Kopetz, Robert A. Wolff, Razelle Kurzrock

Mol Cancer Ther (2013) 12 (12): 2857–2863.

https://doi.org/10.1158/1535-7163.MCT-13-0319-T

Published: 05 December 2013

View articletitled, Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations

Includes: Supplementary data

Journal Articles

Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform.

Mol Cancer Ther (2013) 12 (11_Supplement): A202.

https://doi.org/10.1158/1535-7163.TARG-13-A202

Published: 01 November 2013

View articletitled, Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform.

Journal Articles

Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies.

Filip Janku, Philipp Angenendt, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Veronica R. Holley, Siqing Fu, David S. Hong, Jennifer J. Wheler, Sarina A. Piha-Paul, Ralph G. Zinner, Daniel D. Karp, Vivek Subbiah, Kevin B. Kim, Funda Meric-Bernstam, Frank Diehl, Razelle Kurzrock

Mol Cancer Ther (2013) 12 (11_Supplement): B26.

https://doi.org/10.1158/1535-7163.TARG-13-B26

Published: 01 November 2013

View articletitled, Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies.

Journal Articles

Abstract C69: Phase I trial of lenalidomide and valproic acid in patients with advanced cancer.

Mehmet A. Bilen, Siqing Fu, David S. Hong, Jennifer J. Wheler, Maen Abdelrahim, Gerald S. Falchook, Apostlia M. Tsimberidou, Filip Janku, Sarina Piha-Paul, Ralph Zinner, Razelle Kurzrock, Aung Naing

Mol Cancer Ther (2013) 12 (11_Supplement): C69.

https://doi.org/10.1158/1535-7163.TARG-13-C69

Published: 01 November 2013

View articletitled, Abstract C69: Phase I trial of lenalidomide and valproic acid in patients with advanced cancer.

Journal Articles

Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.

Jennifer J. Wheler, Barbara A. Parker, Jack Lee, Roman Yelensky, Stacy Moulder, Apostolia M. Tsimberidou, Filip Janku, Johnique T. Atkins, Ralph Zinner, Richard Q. Schwab, Maria Schwaederle, Vivek Subbiah, Siqing Fu, Philip J. Stephens, Razelle Kurzrock

Mol Cancer Ther (2013) 12 (11_Supplement): A212.

https://doi.org/10.1158/1535-7163.TARG-13-A212

Published: 01 November 2013

View articletitled, Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.

Journal Articles

Abstract B175: Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR.

Filip Janku, Gerald S. Falchook, Sarina A. Piha-Paul, Aung Naing, Apostolia M. Tsimberidou, Veronica R. Holley, Daniel D. Karp, Ralph G. Zinner, Siqing Fu, Jennifer J. Wheler, David S. Hong, Funda Meric-Bernstam, Vanda M. Stepanek, Rayjalakshmi Luthra, Lorieta Leppin, Latifa Hassaine, Karena Kosco, Jason C. Poole, Mark G. Erlander

Mol Cancer Ther (2013) 12 (11_Supplement): B175.

https://doi.org/10.1158/1535-7163.TARG-13-B175

Published: 01 November 2013

View articletitled, Abstract B175: Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR.

Journal Articles

Abstract B82: Olanzapine for cachexia in patients with advanced cancer.

Maen Abdelrahim, Aung Naing, Shalini Dalal, Jennifer Wheler, Kenneth Hess, Siqing Fu, David S. Hong, Filip Janku, Gerald S. Falchook, Alyson Ilustre, Fengying Ouyang, Razelle Kurzrock

Mol Cancer Ther (2013) 12 (11_Supplement): B82.

https://doi.org/10.1158/1535-7163.TARG-13-B82

Published: 01 November 2013

View articletitled, Abstract B82: Olanzapine for cachexia in patients with advanced cancer.

Journal Articles

Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform.

Mol Cancer Ther (2013) 12 (11_Supplement): C198.

https://doi.org/10.1158/1535-7163.TARG-13-C198

Published: 01 November 2013

View articletitled, Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform.

Journal Articles

Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.

Mol Cancer Ther (2013) 12 (11_Supplement): C203.

https://doi.org/10.1158/1535-7163.TARG-13-C203

Published: 01 November 2013

View articletitled, Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.

Journal Articles

Abstract B191: Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss.

Ming-Mo Hou, Xiaochun Liu, Sarina A. Piha-Paul, Filip Janku, Jennifer Wheler, Aung Naing, Diane Bodurka, Kathleen Schmeler, Karen Lu, Ralph Zinner, David Hong, Funda Meric-Bernstam, Razelle Kurzrock, Siqing Fu

Mol Cancer Ther (2013) 12 (11_Supplement): B191.

https://doi.org/10.1158/1535-7163.TARG-13-B191

Published: 01 November 2013

View articletitled, Abstract B191: Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor

Abstract C067: Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors

Abstract P223: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Abstract C44: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers

Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations

Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform.

Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies.

Abstract C69: Phase I trial of lenalidomide and valproic acid in patients with advanced cancer.

Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.

Abstract B175: Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR.

Abstract B82: Olanzapine for cachexia in patients with advanced cancer.

Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform.

Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.

Abstract B191: Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss.

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only